AGTC Genomics Holds Fruitful Visit and Strategic Discussion with Ministry of Health Malaysia to Advance Precision Medicine in Malaysia

AGTC Genomics Sdn Bhd held a fruitful visit and strategic discussion with the Ministry of Health Malaysia, including YB Datuk Seri Dr. Haji Dzulkefly Ahmad, Minister of Health Malaysia, on potential collaboration to advance precision medicine and precision public health in Malaysia.

The engagement provided an important platform for AGTC Genomics to exchange views with the Ministry of Health on how genomic technologies can support Malaysia’s healthcare transformation, particularly in strengthening early disease detection, improving diagnostic accuracy, enabling personalised treatment, supporting public health preparedness, and building national genomic capacity.

The discussion covered several key areas of healthcare innovation, including cancer early detection, rare disease diagnosis, precision oncology, pharmacogenomics, infectious disease genomics, and precision public health. These areas represent important opportunities for Malaysia to integrate advanced genomic tools into clinical care and population health programmes in a responsible, scalable, and clinically meaningful manner.

As a local Malaysian technology company with BioNexus Pioneer Status in genomics technology, AGTC Genomics reaffirmed its commitment to supporting national healthcare priorities through locally developed expertise, in-country laboratory infrastructure, advanced sequencing platforms, and clinically relevant genomic testing services. AGTC Genomics believes that building strong local capabilities is essential to reduce dependency on overseas testing, improve turnaround time, enhance data governance, and ensure that Malaysian patients and healthcare providers can benefit from timely and reliable genomic insights.

A key strength of AGTC Genomics is its end-to-end precision medicine ecosystem, covering advanced laboratory testing, bioinformatics analysis, clinical interpretation, medical reporting, research translation, and implementation support. This integrated model enables AGTC Genomics to support a wide range of precision healthcare applications, from individual patient care to national-scale public health initiatives.

AGTC Genomics’ laboratory is also recognised as the only genomics laboratory in Malaysia with the combined achievement of ISO 15189, ISO 17025, and College of American Pathologists accreditation, and the winner of the Precision Medicine Solution of the Year Award in Asia Pacific recently, reflecting its strong commitment to clinical quality, analytical reliability, international laboratory standards, and continuous quality improvement.

During the discussion, AGTC Genomics highlighted how its precision medicine platform can contribute to Malaysia’s healthcare priorities across multiple areas. In cancer, genomic technologies can support multi-cancer early detection, comprehensive genomic profiling, therapy selection, and minimal residual disease monitoring. In rare disease, genome sequencing can help shorten the diagnostic journey for patients and families, particularly for complex and undiagnosed conditions. In pharmacogenomics, genomic insights can help guide safer and more effective medication choices. In infectious disease, genomic surveillance can strengthen outbreak detection, pathogen characterisation, antimicrobial resistance monitoring, and precision public health response.

Unlike conventional diagnostic service models that may focus on limited or fragmented testing offerings, AGTC Genomics has developed a broad and integrated precision diagnostics platform covering cancer early detection, comprehensive genomic profiling, minimal residual disease monitoring, rare disease genome sequencing, pharmacogenomics, infectious disease genomics, microbiome analysis, and precision public health applications. This positions AGTC Genomics as a strategic local partner capable of supporting both clinical medicine and public health transformation.

The meeting also emphasised the importance of strengthening Malaysia’s local genomic ecosystem, including laboratory capability, bioinformatics infrastructure, clinical interpretation, workforce training, ethical data governance, quality assurance, and equitable access. AGTC Genomics believes that the successful implementation of precision medicine requires close collaboration between government agencies, public hospitals, clinicians, scientists, universities, industry partners, and patient communities.

“We are honoured to have the opportunity to engage with the Ministry of Health Malaysia and YB Datuk Seri Dr. Haji Dzulkefly Ahmad on the future of precision medicine in the country,” said Professor Chee-Onn Leong, Founder and CEO of AGTC Genomics. “As a Malaysian genomics technology company, AGTC Genomics is committed to working closely with the national healthcare ecosystem to make advanced genomic technologies more accessible, clinically useful, and impactful for Malaysians.”

Professor Leong added that Malaysia has the opportunity to become a regional leader in precision medicine by combining strong public health leadership with local technology capability, internationally accredited laboratory standards, and practical implementation models that can benefit patients across different disease areas.

The visit reflects AGTC Genomics’ continued commitment to supporting Malaysia’s ambition to advance genomic medicine, precision oncology, rare disease diagnosis, pharmacogenomics, infectious disease genomics, and precision public health. Moving forward, AGTC Genomics looks forward to further engagement with the Ministry of Health Malaysia and relevant stakeholders to explore practical collaboration models, pilot initiatives, capacity-building programmes, and implementation pathways that can bring precision medicine closer to patients and communities across Malaysia.

---

About AGTC Genomics

AGTC Genomics Sdn Bhd is a local Malaysian genomics technology company with BioNexus Pioneer Status in genomics technology. The company operates an advanced genomics laboratory that has achieved ISO 15189, ISO 17025, and College of American Pathologists accreditation, making it the only genomics laboratory in Malaysia with this combined quality recognition.

AGTC Genomics focuses on advancing precision medicine through clinical genomics, cancer genomics, rare disease testing, pharmacogenomics, infectious disease genomics, microbiome analysis, and genomic research services. With advanced sequencing technologies, in-country laboratory infrastructure, bioinformatics capability, and strong scientific expertise, AGTC Genomics aims to support clinicians, hospitals, researchers, public health stakeholders, and national healthcare programmes in delivering more precise, personalised, preventive, and data-driven healthcare solutions.